NDA 17033, held by Abraxis Pharm. Heparin Sodium.
As of Nov 13, 2026, NDA 17033 (Heparin Sodium, Sodium Heparin), held by Abraxis Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Heparin Sodium1,000 UNITS/ML · injectable;injection | Heparin Sodium | Discontinued |
| Sodium Heparin5,000 UNITS/ML · injectable;injection | Heparin Sodium | Discontinued |
| Sodium Heparin10,000 UNITS/ML · injectable;injection | Heparin Sodium | Discontinued |
| Sodium Heparin20,000 UNITS/ML · injectable;injection | Heparin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
